Innovative Pharmaceutical Biotech Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Innovative Pharmaceutical Biotech has been growing earnings at an average annual rate of 34.6%, while the Trade Distributors industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 20.1% per year. Innovative Pharmaceutical Biotech's return on equity is 30.9%, and it has net margins of 1568.4%.
Wichtige Informationen
34.6%
Wachstumsrate der Gewinne
34.5%
EPS-Wachstumsrate
| Trade Distributors Wachstum der Industrie | 7.5% |
| Wachstumsrate der Einnahmen | -20.1% |
| Eigenkapitalrendite | 30.9% |
| Netto-Marge | 1,568.4% |
| Letzte Ertragsaktualisierung | 31 Mar 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?
Aug 12
Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)
Jan 05Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?
Feb 18Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.
Nov 26
Aufschlüsselung der Einnahmen und Ausgaben
Wie Innovative Pharmaceutical Biotech Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 24 | 7 | 103 | 13 | 1 |
| 31 Dec 23 | 7 | 84 | 15 | 2 |
| 30 Sep 23 | 8 | 64 | 17 | 4 |
| 30 Jun 23 | 8 | -91 | 17 | 4 |
| 31 Mar 23 | 8 | -246 | 17 | 5 |
| 31 Dec 22 | 8 | -220 | 16 | 4 |
| 30 Sep 22 | 9 | -195 | 15 | 3 |
| 30 Jun 22 | 10 | -75 | 16 | 6 |
| 31 Mar 22 | 11 | 46 | 17 | 8 |
| 31 Dec 21 | 13 | 30 | 18 | 10 |
| 30 Sep 21 | 15 | 14 | 18 | 13 |
| 30 Jun 21 | 15 | -96 | 17 | 9 |
| 31 Mar 21 | 15 | -205 | 17 | 6 |
| 31 Dec 20 | 13 | -200 | 17 | 9 |
| 30 Sep 20 | 11 | -194 | 18 | 11 |
| 30 Jun 20 | 13 | -203 | 20 | 11 |
| 31 Mar 20 | 15 | -211 | 23 | 11 |
| 31 Dec 19 | 17 | -205 | 25 | 7 |
| 30 Sep 19 | 20 | -199 | 27 | 2 |
| 30 Jun 19 | 19 | -230 | 27 | 2 |
| 31 Mar 19 | 19 | -260 | 27 | 2 |
| 31 Dec 18 | 17 | -258 | 30 | 1 |
| 30 Sep 18 | 16 | -256 | 32 | 1 |
| 30 Jun 18 | 16 | -243 | 29 | 1 |
| 31 Mar 18 | 16 | -231 | 26 | 1 |
| 31 Dec 17 | 14 | -237 | 22 | 1 |
| 30 Sep 17 | 13 | -243 | 19 | 1 |
| 30 Jun 17 | 11 | -206 | 21 | 1 |
| 31 Mar 17 | 9 | -170 | 23 | 1 |
| 31 Dec 16 | 10 | -196 | 27 | 1 |
| 30 Sep 16 | 11 | -223 | 31 | 1 |
| 30 Jun 16 | 16 | -230 | 31 | 1 |
| 31 Mar 16 | 20 | -237 | 30 | 1 |
| 31 Dec 15 | 25 | -214 | 25 | 3 |
| 30 Sep 15 | 31 | -190 | 20 | 5 |
| 30 Jun 15 | 32 | -321 | 24 | 5 |
| 31 Mar 15 | 34 | -452 | 28 | 5 |
| 30 Sep 14 | 41 | -891 | 33 | 0 |
| 30 Jun 14 | 39 | -730 | 35 | 0 |
| 31 Mar 14 | 36 | -569 | 37 | 0 |
| 31 Dec 13 | 31 | -522 | 54 | 0 |
Qualität der Erträge: 399 has a large one-off gain of HK$330.2M impacting its last 12 months of financial results to 31st March, 2024.
Wachsende Gewinnspanne: 399 became profitable in the past.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 399 has become profitable over the past 5 years, growing earnings by 34.6% per year.
Beschleunigtes Wachstum: 399 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Erträge im Vergleich zur Industrie: 399 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Trade Distributors industry (1%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: Whilst 399's Return on Equity (30.9%) is high, this metric is skewed due to their high level of debt.